Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system

Acute graft-versus-host disease (GVHD) is a major complication of allogeneic stem cell transplantation (SCT) and can be readily controlled by systemic high-dose steroids in many patients. However, patients whose GVHD is refractory to this therapy have a poor prognosis. Refractory patients have ongoi...

Full description

Saved in:
Bibliographic Details
Main Authors: Luft, Thomas (Author) , Dietrich, Sascha (Author) , Falk, Christine (Author) , Conzelmann, Michael (Author) , Hess, Michael (Author) , Benner, Axel (Author) , Neumann, Frank (Author) , Isermann, Berend (Author) , Hegenbart, Ute (Author) , Ho, Anthony Dick (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: 2011
In: Blood
Year: 2011, Volume: 118, Issue: 6, Pages: 1685-1692
ISSN:1528-0020
DOI:10.1182/blood-2011-02-334821
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2011-02-334821
Verlag, lizenzpflichtig, Volltext: https://ashpublications.org/blood/article/118/6/1685/29155/Steroid-refractory-GVHD-T-cell-attack-within-a
Get full text
Author Notes:Thomas Luft, Sascha Dietrich, Christine Falk, Michael Conzelmann, Michael Hess, Axel Benner, Frank Neumann, Berend Isermann, Ute Hegenbart, Anthony D. Ho, and Peter Dreger
Description
Summary:Acute graft-versus-host disease (GVHD) is a major complication of allogeneic stem cell transplantation (SCT) and can be readily controlled by systemic high-dose steroids in many patients. However, patients whose GVHD is refractory to this therapy have a poor prognosis. Refractory patients have ongoing end-organ damage despite effective immunosuppression with second-line regimens, suggesting pathomechanisms independent from the initiating T-cell attack. To explore whether endothelial damage might contribute to GVHD refractoriness and to study the role of angiopoietin-2 (ANG2) in this process, we have compared kinetics of T-cell activation markers and markers of endothelial dysfunction in the serum of patients with sensitive (n = 23) and refractory GVHD (n = 25). Longitudinal measurements of soluble FAS ligand along with other immune markers demonstrate that refractory patients are not exposed to an overwhelming or unresponsive T-cell attack. However, in contrast to sensitive GVHD, refractory GVHD was associated with rising thrombomodulin levels and high ANG2/ vascular endothelial-derived growth factor ratios. Patients with refractory GVHD showed significantly increased ANG2 levels already before SCT. These results suggest that endothelial cell vulnerability and dysfunction, rather than refractory T-cell activity, drives treatment refractoriness of GVHD and opens new avenues for prediction and control of this devastating condition.
Item Description:Gesehen am 15.11.2022
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2011-02-334821